Victory Capital Management Inc. increased its stake in shares of Haemonetics Corporation (NYSE:HAE) by 18.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,414,526 shares of the medical instruments supplier’s stock after purchasing an additional 381,012 shares during the quarter. Victory Capital Management Inc. owned approximately 4.59% of Haemonetics Corporation worth $108,340,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of HAE. UBS Asset Management Americas Inc. lifted its stake in shares of Haemonetics Corporation by 33.6% during the 1st quarter. UBS Asset Management Americas Inc. now owns 27,411 shares of the medical instruments supplier’s stock worth $1,112,000 after purchasing an additional 6,892 shares during the last quarter. OppenheimerFunds Inc. lifted its stake in shares of Haemonetics Corporation by 27.9% during the 1st quarter. OppenheimerFunds Inc. now owns 18,047 shares of the medical instruments supplier’s stock worth $732,000 after purchasing an additional 3,934 shares during the last quarter. Teachers Advisors LLC lifted its stake in shares of Haemonetics Corporation by 5.1% during the 1st quarter. Teachers Advisors LLC now owns 89,362 shares of the medical instruments supplier’s stock worth $3,625,000 after purchasing an additional 4,337 shares during the last quarter. TIAA CREF Investment Management LLC lifted its stake in shares of Haemonetics Corporation by 1.6% during the 1st quarter. TIAA CREF Investment Management LLC now owns 208,457 shares of the medical instruments supplier’s stock worth $8,457,000 after purchasing an additional 3,310 shares during the last quarter. Finally, Legal & General Group Plc lifted its stake in shares of Haemonetics Corporation by 0.8% during the 1st quarter. Legal & General Group Plc now owns 91,350 shares of the medical instruments supplier’s stock worth $3,706,000 after purchasing an additional 733 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This news story was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://theolympiareport.com/2017/11/02/victory-capital-management-inc-has-108-34-million-position-in-haemonetics-corporation-hae.html.

Haemonetics Corporation (NYSE:HAE) last released its earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.02. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. The firm had revenue of $211.00 million during the quarter, compared to analysts’ expectations of $211.29 million. During the same period in the previous year, the firm posted $0.25 EPS. Haemonetics Corporation’s revenue for the quarter was up .5% on a year-over-year basis.

A number of equities research analysts recently weighed in on HAE shares. Zacks Investment Research upgraded Haemonetics Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. JMP Securities upgraded Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 price objective for the company in a research note on Thursday, July 13th. BidaskClub cut Haemonetics Corporation from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 27th. Jefferies Group LLC restated a “buy” rating and set a $48.00 price objective on shares of Haemonetics Corporation in a research note on Thursday, July 27th. Finally, Barrington Research upgraded Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price objective for the company in a research note on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $45.83.

Haemonetics Corporation Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.